CRISPR Technology: From Bench to Bedside Applications
MedComm · 2026-11 · 7 (11)
DOI: 10.1002/mco2.71011 ↗Abstract
ABSTRACT CRISPR‐Cas genome editing represents one of the most transformative advances in modern molecular biology, enabling programmable site‐specific genetic modification that has revolutionized functional genomics and precision therapeutic development. Beyond canonical Cas9 nucleases, the CRISPR toolkit has diversified into precision base editors, prime editors, CRISPR‐associated transposases, and Cas12/Cas13 RNA‐targeting effectors, each with distinct mechanistic properties. Clinically, ex vivo CRISPR therapies for hemoglobinopathies have secured regulatory approval, while base editing, prime editing, and in vivo Chimeric Antigen Receptor (CAR)‐T candidates are advancing through trials for a broad spectrum of hematologic, oncologic, and rare genetic disorders. However, existing reviews largely address technical innovation or clinical translation in isolation, lacking a holistic, up‐to‐date synthesis of the full bench‐to‐bedside trajectory of CRISPR technology. This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms; summarizes pivotal clinical data across hemoglobinopathies, CAR‐T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases and rare monogenic diseases; evaluates delivery systems including lipid nanoparticles and viral vectors; and discusses key translational barriers such as off‐target genotoxicity and immunogenicity alongside emerging optimization strategies. This work provides a holistic bench‐to‐bedside framework for CRISPR research, offering critical insights to advance next‐generation precision genetic medicine.
EUVIMED